Summit Therapeutics rises as traders buy dip after Q1 loss, eye ivonescimab catalysts
SMMT•Summit Therapeutics (SMMT) is higher after a sharp selloff late last week tied to its Q1 2026 update that showed a much wider net loss as it ramped spending on late-stage ivonescimab trials. With no new company press release on May 4, the move appears driven by dip-buying and positioning ahead of upcoming oncology catalysts, with elevated short interest adding fuel.
1. What’s moving the stock today
Summit Therapeutics shares are up about 3.8% to roughly $17.36 in Monday’s session (May 4, 2026), rebounding modestly after a steep decline on May 1 that followed the company’s first-quarter 2026 financial update and operational progress disclosure. There was no fresh May 4 company press release or SEC filing indicating a new fundamental catalyst; the day’s gains look consistent with post-selloff bargain hunting and re-risking into a volatile biotech name ahead of the next major updates around its lead asset, ivonescimab. ()
